Expression of SATB1 is a prognostic indicator for survival in diffuse large B-cell lymphoma patients

H. Yi, Y. Wei, J.-J. Chen

Department of Oncology, Pulmonary and Critical Care Medicine, Guigang City People’s Hospital, Guigang, Guangxi Zhuang Autonomous Region, China. jinjing_chen228815@163.com

---

• Oncology

OBJECTIVE: Special AT-rich Sequence-binding Protein-1 (SATB1) and Matrix Attachment Region-binding Protein were associated with high tumor stage, tumor recurrence, tumor-related death and indicating a poor prognosis. The association between SATB1 and diffuse large B-cell lymphoma (DLBCL) has been discussed controversially. Thence, this study anticipated probing the expression of SATB1 in DLBCL and the relationships with clinic pathological features and prognosis.

PATIENTS AND METHODS: 180 cases of DLBCL tissues and 180 cases of chronic Lymphadenitis tissues in Para-carcinoma of DLBCL patients were collected in Guigang City People’s Hospital, Guangxi, China, from August 2010 to December 2018. Here, the expression pattern of SATB1 in patients was examined by the method of streptomycin peroxides biotin (SP) immunohistochemical and analyzed the relationship of SATB1 with clinical pathological features and patient prognosis.

RESULTS: DLBCL carcinoma tissues expression SATB1 was significantly higher than chronic lymphadenitis tissues (p < 0.05), and the expression of SATB1 was not correlated with age, B symptoms and the ECOG status of patients (p> 0.05), but correlated with tumor stage, serum level of LDH, extranodal involvement, and IPI score (p < 0.05). Kaplan-Meier curves and multivariate analysis showed that SATB1 is an independent factor affecting progression-free survival time and overall survival time.

CONCLUSIONS: SATB1 participates in and affects the occurrence and development of DLBCL and influences their prognosis. It has broad prospects for improving prognosis evaluation, feasibility, molecular treatment intention and allocation of the most appropriate therapy.

Free PDF Download